These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21709063)

  • 1. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
    Lazar LD; Pletcher MJ; Coxson PG; Bibbins-Domingo K; Goldman L
    Circulation; 2011 Jul; 124(2):146-53. PubMed ID: 21709063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary prevention of coronary heart disease with statins: it's not about the money.
    Schwartz JS
    Circulation; 2011 Jul; 124(2):130-2. PubMed ID: 21747064
    [No Abstract]   [Full Text] [Related]  

  • 3. Statins for cardiovascular prevention according to different strategies: a cost analysis.
    Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
    Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
    van Hout BA; Simoons ML
    Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
    Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
    Walshe V; Nash A; Barry M
    Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2010; 10(6):369-82. PubMed ID: 21090830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug insight: Statin use in the elderly.
    Raffel OC; White HD
    Nat Clin Pract Cardiovasc Med; 2006 Jun; 3(6):318-28. PubMed ID: 16729010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of statins in coronary heart disease.
    Franco OH; Peeters A; Looman CW; Bonneux L
    J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy.
    Lee KK; Cipriano LE; Owens DK; Go AS; Hlatky MA
    Circulation; 2010 Oct; 122(15):1478-87. PubMed ID: 20876434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the 1998 Canadian cholesterol guidelines to a military population: health benefits and cost effectiveness of improved cholesterol management.
    Spaans JN; Coyle D; Fodor G; Nair R; Vaillancourt R; Grover SA; Coupal L
    Can J Cardiol; 2003 Jun; 19(7):790-6. PubMed ID: 12813612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care.
    Kedward J; Dakin L
    Br J Gen Pract; 2003 Sep; 53(494):684-9. PubMed ID: 15103875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
    Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
    Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD; Patel H
    Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations.
    Ellis JJ; Erickson SR; Stevenson JG; Bernstein SJ; Stiles RA; Fendrick AM
    J Gen Intern Med; 2004 Jun; 19(6):638-45. PubMed ID: 15209602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.